Anti-tumour necrosis factor treatment does not increase cancer risk in RA patients
Thursday, October 29, 2009 - 05:00
in Health & Medicine
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumour necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of Arthritis and Rheumatism, a journal of the American College of Rheumatology published by Wiley-Blackwell...